Regenetech licenses cellXpansion to KSCB
US stem cell specialist Regenetech has licensed its proprietary stem cell expansion technology cellXpansion to the Korea Stem Cell Bank company. The deal covers the latter's use of cellXpansion in South Korea and, following last year's agreement with Mexico's Regenevita (Marketletter November 12, 2007), is the latest in a series of country-specific licenses that the US firm has granted.
David Bonner, chief executive of the Houston-headquartered firm, said that he was delighted that "KSCB has chosen to partner with Regenetech and our strong cellXpansion technology in order to expand stem cells." He went on to say that deals of this type, financial terms of which were not disclosed, are integral to the company's future development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze